IP Library › Granted Patent US 7,666,837
Granted Patent B2
US 7,666,837 · App. 11/643,568 · Granted Feb 23, 2010

Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins

Assignee: GenHunter Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,666,837
App. No.
11/643,568
Granted
Feb 23, 2010
Kind
B2
Abstract

Methods and compositions for producing secreted soluble receptors and biologically active polypeptides in trimeric forms are disclosed. The process involves fusing the DNA template encoding a soluble receptor with a ligand binding domain or biologically active polypeptide to a DNA sequence encoding a C-propeptide of collagen, which is capable of self-assembly into a covalently linked trimer. The resulting fusion proteins are secreted as trimeric soluble receptor analogs, which can be used for more efficient neutralization of the biological activities of their naturally occurring trimeric ligands.

Claims (9)

1. An isolated nucleic acid comprising consecutive nucleotides having a nucleotide sequence encoding a fused protein subunit comprising a signal peptide joined by in-frame fusion to a non-collagenous polypeptide comprising a ligand binding domain, which in turn is joined by in-frame fusion to a C-terminal portion of collagen which is capable of self-trimerizing said fused protein subunit to form a disulfide bond-linked trimeric fusion protein containing three ligand binding domains, wherein said trimeric fusion protein has a greater binding affinity to a ligand than a monomeric ligand binding domain.

2. The nucleic acid of claim 1 , wherein the C-terminal portion of collagen encoded by the nucleic acid is selected from the group consisting of pro.alpha.1(I), pro.alpha 2(I), pro.alpha.1(II), pro.alpha.1(III), pro.alpha.1(V), pro.alpha.2(V), pro.alpha.1(XI), pro.alpha.2(XI) and pro.alpha.3(XI).

3. The nucleic acid of claim 1 , wherein the signal peptide and the non-collagenous polypeptide are selected from two different secreted proteins.

4. The nucleic acid of claim 1 , wherein the signal peptide and the non-collagenous polypeptide are both from an identical native secreted protein.

5. The nucleic acid of claim 1 , wherein the nucleic acid encodes the C-terminal portion of collagen having only a C-propeptide without any linked glycine-repeat triple helical regions of collagen.

6. The nucleic acid of claim 1 , wherein the nucleic acid encodes the C-terminal portion of collagen having a glycine-repeat triple helical region of collagen linked to a C-propeptide.

7. The nucleic acid of claim 6 , wherein the nucleic acid encodes the C-terminal portion of collagen having an amino acid sequence shown as SEQ ID NO:2.

8. The nucleic acid of claim 1 , wherein the nucleic acid encodes the C-terminal portion of collagen having a mutated or deleted BMP-1 protease recognition sequence.

9. The nucleic acid of claim 8 , wherein the C-terminal portion of collagen encoded by the nucleic acid is selected from the group consisting of SEQ ID NO:4 and SEQ ID NO: 18.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: LIANG, PENG
To: GENHUNTER CORPORATION
Reel/Frame 055739/0777 →
Continuity (2)
Continuation In Part 1067787700 · Oct 2, 2003
Related Publication 20070087413A1 · Apr 19, 2007